Incyte Corporation

ACTIVE

Wilmington, Delaware, USA, 美国www.incyte.comPublic2,617 名员工成立于: 1991-04-08255亿美元

别名:

incyte corp.

American multinational pharmaceutical company headquartered in Wilmington, Delaware; develops and manufactures prescription biopharmaceutical medications across oncology, inflammation, and autoimmunity therapeutic areas.

概览

试验阶段分布

阶段

试验数

占比

1 期

51.8%

3 期

31.8%

2 期

16.5%

试验状态分布

进行中（未招募）

10.6%

已完成

7.1%

招募中

81.2%

撤回

1.2%

相关临床试验

该机构主办的试验（85）

A First-in-Human Study of INCA035784 in Participants With Myeloproliferative Neoplasms

1 期

招募中

Oct 202640 名受试者

A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms

1 期

招募中

Sep 202660 名受试者

A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

1 期

招募中

Jul 2026150 名受试者

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

3 期

招募中

Jun 2026292 名受试者

A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

3 期

招募中

Apr 2026239 名受试者

IMPD-Q-only application

1 期

撤回

Mar 202630 名受试者

Phase 3 Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression

3 期

招募中

Feb 2026308 名受试者

A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors

第 1 页，共 11 页

药物批准

暂无批准数据

资讯

暂无资讯文章

返回机构列表